<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12604544
   </pmid>
   <datecreated>
    <year>
     2003
    </year>
    <month>
     02
    </month>
    <day>
     26
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     08
    </month>
    <day>
     14
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0066-4804
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       47
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2003
       </year>
       <month>
        Mar
       </month>
      </pubdate>
     </journalissue>
     <title>
      Antimicrobial agents and chemotherapy
     </title>
     <isoabbreviation>
      Antimicrob. Agents Chemother.
     </isoabbreviation>
    </journal>
    <articletitle>
     High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies.
    </articletitle>
    <pagination>
     <medlinepgn>
      1072-80
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Oral valacyclovir is better absorbed than oral acyclovir, increasing acyclovir bioavailability three- to fivefold. This provides the opportunity to explore whether high systemic acyclovir concentrations are effective in the treatment of cold sores (herpes labialis). Two randomized, double-blind, placebo-controlled studies were conducted. Subjects were provided with 2 g of valacyclovir twice daily for 1 day (1-day treatment), 2 g of valacyclovir twice daily for 1 day and then 1 g of valacyclovir twice daily for 1 day (2-day treatment), or a matching placebo and instructed to initiate treatment upon the first symptoms of a cold sore. In study 1, the median duration of the episode (primary endpoint) was reduced by 1.0 day (P = 0.001) with 1-day treatment and 0.5 days (P = 0.009) with 2-day treatment compared to placebo. Similarly, the mean duration of the episode was statistically significantly reduced by 1.1 days with 1-day treatment and 0.7 days with 2-day treatment compared to placebo. The proportion of subjects in whom cold sore lesion development was prevented and/or blocked was increased by 6.4% (P = 0.096) with 1-day treatment and 8.5% (P = 0.061) with 2-day treatment compared to placebo. The time to lesion healing and time to cessation of pain and/or discomfort were statistically significantly reduced with valacyclovir compared to placebo. In study 2, results similar to those in study 1 were obtained. AEs were similar across treatment groups. These studies provide evidence supporting a simple, 1-day valacyclovir treatment regimen for cold sores that is safe and effective. The 1-day valacyclovir regimen offers patients a unique and convenient dosing alternative compared to available topical therapies.
     </abstracttext>
    </abstract>
    <affiliation>
     University of Utah, Division of Infectious Diseases, School of Medicine, Salt Lake City 84132, USA. woody.spruance@hsc.utah.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Spruance
      </lastname>
      <forename>
       Spotswood L
      </forename>
      <initials>
       SL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Jones
      </lastname>
      <forename>
       Terry M
      </forename>
      <initials>
       TM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Blatter
      </lastname>
      <forename>
       Mark M
      </forename>
      <initials>
       MM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Vargas-Cortes
      </lastname>
      <forename>
       Mauricio
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Barber
      </lastname>
      <forename>
       Judy
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hill
      </lastname>
      <forename>
       Joanne
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Goldstein
      </lastname>
      <forename>
       Donna
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Schultz
      </lastname>
      <forename>
       Margaret
      </forename>
      <initials>
       M
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Antimicrob Agents Chemother
    </medlineta>
    <nlmuniqueid>
     0315061
    </nlmuniqueid>
    <issnlinking>
     0066-4804
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antiviral Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      124832-27-5
     </registrynumber>
     <nameofsubstance>
      valacyclovir
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      59277-89-3
     </registrynumber>
     <nameofsubstance>
      Acyclovir
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      7004-03-7
     </registrynumber>
     <nameofsubstance>
      Valine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Oral Surg Oral Med Oral Pathol. 1976 Apr;41(4):498-507
     </refsource>
     <pmid version="1">
      1063349
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Antivir Chem Chemother. 1998 Jan;9(1):19-24
     </refsource>
     <pmid version="1">
      9875373
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arch Dermatol. 2001 Sep;137(9):1232-5
     </refsource>
     <pmid version="1">
      11559222
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Can Med Assoc J. 1975 Oct 4;113(7):627-30
     </refsource>
     <pmid version="1">
      1181018
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Am Dent Assoc. 2002 Mar;133(3):303-9
     </refsource>
     <pmid version="1">
      11934185
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Antimicrob Agents Chemother. 2002 Jul;46(7):2238-43
     </refsource>
     <pmid version="1">
      12069980
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1990 Feb;161(2):185-90
     </refsource>
     <pmid version="1">
      2153735
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1978 Dec;138(6):897-905
     </refsource>
     <pmid version="1">
      216753
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Stat Med. 1990 Jul;9(7):811-8
     </refsource>
     <pmid version="1">
      2218183
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Am Dent Assoc. 1987 Jul;115(1):38-42
     </refsource>
     <pmid version="1">
      3301980
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Oral Surg Oral Med Oral Pathol. 1984 Dec;58(6):667-71
     </refsource>
     <pmid version="1">
      6095159
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br Med J (Clin Res Ed). 1983 May 28;286(6379):1699-701
     </refsource>
     <pmid version="1">
      6405939
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Am Acad Dermatol. 1981 Nov;5(5):550-7
     </refsource>
     <pmid version="1">
      7298921
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Antimicrob Agents Chemother. 1995 Dec;39(12):2759-64
     </refsource>
     <pmid version="1">
      8593015
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1997 May 7;277(17):1374-9
     </refsource>
     <pmid version="1">
      9134943
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arch Dermatol. 2001 Sep;137(9):1153-8
     </refsource>
     <pmid version="1">
      11559210
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Acyclovir
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antiviral Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Herpes Labialis
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pain
     </descriptorname>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Valine
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC149313
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2003
     </year>
     <month>
      2
     </month>
     <day>
      27
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      8
     </month>
     <day>
      15
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2003
     </year>
     <month>
      2
     </month>
     <day>
      27
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12604544
    </articleid>
    <articleid idtype="pmc">
     PMC149313
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

